Physicians' Academy for Cardiovascular Education

What is the situation one year after the presentation about the CANTOS trial?

CSI Munich

10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA

Video navigation menu

  • Implementation of canakinumab in daily practice 0:52
  • Distinction responders and non-responders in CANTOS trial 2:51
  • Dosis-dependent effect of canakinumab 4:44
  • Cost-effectiveness of canakinumab 5:17
  • IL-1beta inhibition in primary prevention 8:24
  • Vision about canakinumab 9:33

Educational information

In the Cardiovascular Scene Investigation (CSI) series, investigators from Utrecht report at the ESC congress, from perspective of young investigators. They put a question to researchers about presented study results.


Prof. Paul Ridker, MD - Brigham and Women's hospital, Boston, MA, USA


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Share this page with your colleagues and friends: